Glaukos Corporation
GKOSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and. At a $10.91B market cap, Glaukos Corporation ranks as a large-cap company within healthcare. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Market Cap
$10.91B
Beta
0.77
P/E (TTM)
—
P/E (Fwd)
366.90
EPS (TTM)
$-3.27
EPS (Fwd)
$0.50
ROE
-26.0%
ROA
-5.2%
Cash
$286.2M
Total Debt
$107.6M
Free CF
$15.5M
52W Change
102.8%
Annual Financials
Cash vs Debt
Where GKOS stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, GKOS finished 37.28% above its 150-day moving average ($132.13) and 44.32% above its 200-day moving average ($125.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GKOS overbought or oversold?
At the August 26, 2026 close, GKOS's RSI(14) was 62.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $286.2M in cash and $107.6M in debt, GKOS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $15.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -26.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $282.9M (2022) to $507.4M (2025), reflecting a 79% increase over the period.
With cash comfortably exceeding debt, GKOS has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Glaukos Corporation's trajectory.